CPA
LXRX icon

Capital Performance Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

Capital Performance Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-18
Closed -$28 – 1595
2024
Q3 		$28 Buy
+18
New +$32 ﹤0.01% 2840

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Performance Advisors's LXRX Position: Q4 2024 in Review

Capital Performance Advisors sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2024, closing a stake of 18 shares — an estimated $28 sold.

Capital Performance Advisors first reported a position in LXRX in Q3 2024 and held it in 1 quarter. The position peaked at $28 in Q3 2024. 127 funds tracked by Wall St. Rank hold LXRX as of Q4 2024.

  • Capital Performance Advisors reported no remaining Lexicon Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 18 Lexicon Pharmaceuticals shares in Q4 2024, an estimated $28.
  • Capital Performance Advisors first reported a position in Lexicon Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Lexicon Pharmaceuticals position peaked at $28 in Q3 2024.
  • 127 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.